ESPR / Esperion Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

As filed with the Securities and Exchange Commission on August 13, 2025

As filed with the Securities and Exchange Commission on August 13, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics

Esperion Reports Preliminary Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equ

Exhibit 99.1 Correcting and Replacing: Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update Esperion Therapeutics, Inc. (the “Company”) is replacing in its entirety its earnings press release for the second quarter ended June 30, 2025, originally issued on August 5, 2025 (the “Earnings Release”), to correct certain disclosures contained in the tables entitled “Balanc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER: 001-35986 CUSIP NUMBER: 29664W105 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Trans

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Inc

Exhibit 99.1 Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 Esperion Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Esperion Appoints Craig Thompson to Board of Directors – Brings More Than Twenty Years of Biopharmaceutical Leadership Experience –

Exhibit 99.1 Esperion Appoints Craig Thompson to Board of Directors – Brings More Than Twenty Years of Biopharmaceutical Leadership Experience – ANN ARBOR, Mich., July 1, 2025 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thomps

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2025 Esperion Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 29, 2025 Esperion Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 29, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

Amendment to 2022 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on

Exhibit 10.1 ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Esperion Therapeutics, Inc. (the “Company”) a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutic

irst Supplemental Indenture, dated as of January 27, 2025

firstsupplementalindentu FIRST SUPPLEMENTAL INDENTURE Dated as of January 27, 2025 to the INDENTURE Dated as of December 17, 2024 Between ESPERION THERAPEUTICS, INC.

Esperion Reports First Quarter 2025 Financial Results – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y

Exhibit 99.1 Esperion Reports First Quarter 2025 Financial Results – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Esperion Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

Up to $70,000,000 of Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-286631 PROSPECTUS Up to $70,000,000 of Shares of Common Stock We have previously entered into a Controlled Equity OfferingSM Sales Agreement (the “sales agreement”), dated February 21, 2023, with Cantor Fitzgerald & Co. (“Cantor”), relating to the sale of shares of our common stock, par value $0.001 per share, offered by thi

VIA EDGAR

VIA EDGAR April 25, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.4 ESPERION THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.01 Designation and Terms of Securities Section 2.02 Form of Securities and Trustee’s Certificate Se

As filed with the Securities and Exchange Commission on April 18, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 18, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Esperion Therapeutics, Inc.

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.5 ESPERION THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 202[·] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.0 Designation and Terms of Securities Section 2.02 Form of Securities and Trustee’s Certifica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2025 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Esperion Appoints Robert E. Hoffman to Board of Directors – Veteran Industry Executive Brings Decades of Financial and Leadership Experience –

Exhibit 99.1 Esperion Appoints Robert E. Hoffman to Board of Directors – Veteran Industry Executive Brings Decades of Financial and Leadership Experience – ANN ARBOR, Mich., April 1, 2025 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2025 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 1, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA

\ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion The

Esperion Therapeutics, Inc. Insider Trading Policy

Exhibit 19.1 Esperion Therapeutics, Inc. Insider Trading Policy PURPOSE This policy sets forth the policy and procedures of Esperion Therapeutics, Inc. (the "Company") regarding trading in the Company's securities for the Company’s directors, officers, and employees designated as "Insiders." SCOPE This policy is applicable to all directors, officers, and employees who are designated "Insiders." Mo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2025 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Pr

Exhibit 99.1 Esperion Reports Fourth Quarter and Full Year 2024 Financial Results – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars

Slides from Presentation of the Company, dated January 15, 2025.

Exhibit 99.1

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2025 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

Indenture dated as of December 17, 2024, between Esperion Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as Trustee.

Exhibit 4.1 Execution Version ESPERION THERAPEUTICS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 17, 2024 5.75% Convertible Senior Subordinated Notes due 2030 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 14 Article 2 Issue, Description, Execution, Registration and Exchange of Note

Credit Agreement, dated as of December 13, 2024, by and among Esperion Therapeutics, Inc., GLAS USA LLC, as administrative agent, and the lenders party thereto.

Exhibit 10.1 Execution Version CREDIT AGREEMENT Dated as of December 13, 2024 among ESPERION THERAPEUTICS, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER, as the Guarantors, GLAS USA LLC and GLAS AMERICAS LLC, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page Article I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms 1 1.02 Other In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2024 Esperion Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

ESPERION ANNOUNCES $210 MILLION CONVERTIBLE DEBT FINANCING

Exhibit 99.1 ESPERION ANNOUNCES $210 MILLION CONVERTIBLE DEBT FINANCING ANN ARBOR, Mich., December 13, 2024 (GLOBE NEWSWIRE) - Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursua

ESPR / Esperion Therapeutics, Inc. / Two Seas Capital LP Passive Investment

SC 13G/A 1 formsc13ga-esperion.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 2966

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 Esperion Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription E

Exhibit 99.1 Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therape

ESPR / Esperion Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G/A 1 ESPRSC13GA1Oct2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Chec

As filed with the Securities and Exchange Commission on August 12, 2024

As filed with the Securities and Exchange Commission on August 12, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 Esperion Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commis

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription

Exhibit 99.1 Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformationa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics

Royalty Purchase Agreement by and between the Registrant and OCM IP Healthcare Portfolio LP dated as of June 24, 2024

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ROYALTY PURCHASE AGREEMENT ESPERION THERAPEUTICS, INC. as Seller - and - OCM IP HEALTHCARE PORTFOLIO LP as Purchaser June 27, 2024 TABLE OF CONTENTS ARTICLE 1 DEFINED TERMS AND RULES OF CONSTRUCTION

Transition Agreement, dated August 3, 2024, by and between Esperion Therapeutics, Inc. and JoAnne Foody.

Exhibit 10.1 TRANSITION AGREEMENT This Transition Agreement (“Agreement”) is made between Esperion Therapeutics, Inc., a Delaware corporation and its subsidiaries (the “Company”) and JoAnne Foody, MD (the “Executive”). Terms with initial capitalization not otherwise defined shall have the meanings ascribed to such terms in the Employment Agreement (as defined below). WHEREAS, the Executive serves

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility – OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with Europea

Exhibit 99.1 Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility – OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Potential Futur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2024 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

ESPR / Esperion Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G 1 ESPRSC13GJune2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) JUNE 10, 2024 (Date of event which requires filing of this statement) Check the appropriate box to d

Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan, as amended, and forms of agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on May 28, 2024)

Exhibit 10.1 ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Esperion Therapeutics, Inc. (the “Company”) a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on May 28, 2024)

Exhibit 10.2 ESPERION THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("the Plan") is to provide eligible employees of Esperion Therapeutics, Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.001 per sha

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutic

Confidential Settlement Agreement and Release, dated as of January 2, 2024, between the Registrant and Daiichi Sankyo Europe GmbH**

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE This Confidential Settlement Agreement and Release (the “Settlement Agreement”) is made and entered into as of January 2, 2024 (the “SA Effective Date”)

1st Amendment to License and Collaboration Agreement, by and between the Registrant and Daiichi Sankyo Company, Limited dated January 2, 2024**

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 1st AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT by and between DAIICHI SANKYO COMPANY, LIMITED and ESPERION THERAPEUTICS, INC. January 2, 2024 THIS 1st AMENDMENT to the LICENSE AND COLLABOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 Esperion Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43%

Exhibit 99.1 Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expan

3rd Amendment to the License and Collaboration Agreement by and between the Registrant and Daiichi Sankyo Europe GMBH dated January 2, 2024 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, File No. 001-35986, filed on May 7, 2024)

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 3rd AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT by and between DAIICHI SANKYO EUROPE GMBH and ESPERION THERAPEUTICS, INC. January 2, 2024 THIS 3rd AMENDMENT to the LICENSE AND COLLABORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Esperion Therapeutics, Inc.

Exhibit 97.1 ESPERION THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of November 8, 2023 Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview This Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

\ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2024 Esperion Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

Exhibit 4.4

Exhibit 4.4 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Esperion Therapeutics, Inc. (“Esperion,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results – FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 To

Exhibit 99.1 Esperion Reports Fourth Quarter and Full Year 2023 Financial Results – FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total Revenue Grew 72% Y/Y to $32.3 Million – – Q4 Retail Prescription Equivalents Grew 44% Y/Y and 8% Q/Q, with Momentum Expected into 1H

ESPR / Esperion Therapeutics, Inc. / Two Seas Capital LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2

ESPR / Esperion Therapeutics, Inc. / Point72 Asset Management, L.P. - ESPERION THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0795sc13ga.htm ESPERION THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta

ESPR / Esperion Therapeutics, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 tm244732d3sc13ga.htm SC 13G/A CUSIP No: 29664W105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 3)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title

ESPR / Esperion Therapeutics, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

ESPR / Esperion Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0873-esperiontherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Esperion Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 29664W105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A 1 d879509dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) January 19, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d

ESPR / Esperion Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A 1 d155477dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to

Underwriting Agreement, dated as of January 18, 2024, by and between Esperion Therapeutics, Inc. and Jefferies LLC, as representative of the several underwriters listed on Schedule A thereto.

Exhibit 1.1 56,700,000 Shares Esperion Therapeutics, Inc. UNDERWRITING AGREEMENT January 18, 2024 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Esperion Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Esperion Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35986 26-1870780 (State or Other Jurisdiction of Incorporation) (Commi

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

Exhibit 99.2 Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock January 19, 2024 ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) - Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per

56,700,000 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration Statement No. 333-264303 Prospectus Supplement (to Prospectus dated April 26, 2022) 56,700,000 Shares of Common Stock We are offering 56,700,000 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of common stock is $

Esperion Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Esperion Announces Proposed Public Offering of Common Stock January 18, 2024 ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) - Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with this offering, Esperion expects to grant the underwriters a 30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2024 Esperion Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2024 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Shares of Common Stock

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

ESPR / Esperion Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2024 (January 10, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2024 (January 10, 2024) Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of in

Slides from Presentation of the Company, dated January 10, 2024.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 (January 2, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 (January 2, 2024) Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of inco

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation – Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decisi

Exhibit 99.1 Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation – Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet – – Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therape

Esperion Reports Third Quarter 2023 Financial Results – Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained

Exhibit 99.1 Esperion Reports Third Quarter 2023 Financial Results – Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Acceptance of Application for Expanded CV Risk Reduction Indications with PDUFA Date of March 31;

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

ESPR / Esperion Therapeutics Inc. / Two Seas Capital LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29664W105 (CUSIP Number) N/A (Date of Ev

ESPR / Esperion Therapeutics Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) AUGUST 28, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to

ESPR / Esperion Therapeutics Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) AUGUST 21, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to

As filed with the Securities and Exchange Commission on August 24, 2023

As filed with the Securities and Exchange Commission on August 24, 2023 Registration No.

Second Amendment to 2017 Inducement Equity Plan (incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8, File No. 333-274183, filed on August 24, 2023)

Exhibit 99.3 SECOND AMENDMENT TO ESPERION THERAPEUTICS, INC. 2017 INDUCEMENT EQUITY PLAN A.The Esperion Therapeutics, Inc. 2017 Inducement Equity Plan (the “Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,650,000 shares, subject to a

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

Esperion Reports Second Quarter 2023 Financial Results – Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded

Exhibit 99.1 Esperion Reports Second Quarter 2023 Financial Results – Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded Indications in the U.S. and Europe; Label Changes Expected in 1H 2024 – – Presented New CLEAR Outcomes Analysis, Demonstrating Significa

As filed with the Securities and Exchange Commission on August 1, 2023

As filed with the Securities and Exchange Commission on August 1, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2023 Esperion Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2023 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions – 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key

Exhibit 99.1 Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions – 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause mortality – – Bempedoic acid is the first LDL-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2023 Esperion Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

First Amendment to 2022 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report

Exhibit 10.1 ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Esperion Therapeutics, Inc. (the “Company”) a

Certificate of Amendment No. 2 to Amended and Restated Certificate of Incorporation of the Registrant

Exhibit 3.1 CERTIFICATE OF AMENDMENT NO. 2 TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ESPERION THERAPEUTICS, INC. (Pursuant to Section 242 of the Delaware General Corporation Law) Esperion Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the “DGCL”), does hereby certify as follow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Esperion Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutic

Esperion Reports First Quarter 2023 Financial Results – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position w

Exhibit 99.1 Esperion Reports First Quarter 2023 Financial Results – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global Regulatory Filings Anticipated in 1H 2023 – – Entered into Commercial Partnership with Currax Pha

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37

Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37 Plaintiff Esperion Therapeutics, Inc.

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 – Gibson Dunn Files Amended Complaint with Powerful New Evidence –

Exhibit 99.2 Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 – Gibson Dunn Files Amended Complaint with Powerful New Evidence – ANN ARBOR, Mich., May 4, 2023 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99 2 exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the neces

ESPR / Esperion Therapeutics Inc. / Point72 Asset Management, L.P. - ESPERION THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29664W105 (CUSIP Number) April 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Case 1:23-cv-02568 Document 1 Filed 03/27/23 Page 1 of 9 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Case 1:23-cv-02568 Document 1 Filed 03/27/23 Page 1 of 9 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK COMPLAINT 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2023 Esperion Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Form of Securities Purchase Agreement

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2023, between Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit

Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.2 Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents i

Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.1 Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of it

Form of Common Stock Purchase Warrant

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Esperion Therapeutics, Inc. Warrant Shares: Issue Date: , 2023 Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 22, 2023  (March 19, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 22, 2023  (March 19, 2023) Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incor

9,024,212 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants Common Warrants to Purchase up to 9,024,212 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-258397 PROSPECTUS SUPPLEMENT Dated March 22, 2023 (To Prospectus Dated August 3, 2021) 9,024,212 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants Common Warrants to Purchase up to 9,024,212 Shares of Common Stock This prospectus supplement (the “Sticker Supplement”) modifies, supersedes and supplements certain information c

Form of Pre-Funded Common Stock Purchase Warrant

Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ESPERION THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Form of Warrant Amendment Agreement

Exhibit 10.2 March 19, 2023 Holder of Warrants to Purchase Common Stock issued in December 2021 Re: Amendment to Existing Warrant Dear Holder: Reference is hereby made to the concurrent registered offering on or about the date hereof (the “Offering”) by Esperion Therapeutics, Inc. (the “Company”) of its securities (collectively, the “Securities”). This letter confirms that, in consideration for (i

12,205,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 20,965,747 Shares of Common Stock Warrants to Purchase up to 33,170,747 Shares of Common Stock Up to 54,136,494 Shares of Common Stock underlying such Pre-Funded Warrants and War

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-264303 Prospectus Supplement (to Prospectus dated April 26, 2022) 12,205,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 20,965,747 Shares of Common Stock Warrants to Purchase up to 33,170,747 Shares of Common Stock Up to 54,136,494 Shares of Common Stock underlying such Pre-Funded Warrants and Warrants Espe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2023 Esperion Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients Results De

Exhibit 99.1 Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NE

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Up to $70,000,000 of Shares Common Stock

TABLE OF CONTENTS   Filed Pursuant to Rule 424(b)(5)  Registration No. 333-264303 PROSPECTUS SUPPLEMENT (To prospectus dated April 26, 2022) Up to $70,000,000 of Shares Common Stock We have entered into a Controlled Equity Offering SM Sales Agreement, or the sales agreement, dated February 21, 2023, with Cantor Fitzgerald & Co., or Cantor, relating to the sale of shares of our common stock, par va

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update – Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secon

Exhibit 99.1 Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update – Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secondary Endpoints; Additional Details in 11 Days at ACC.23/WCC – – Generated $15M in U.S. Net Sales in Q4 (+23% vs Q4 2021) and Full Year U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

\ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion The

Controlled Equity OfferingSM Sales Agreement, by and between Esperion Therapeutics, Inc. and Cantor Fitzgerald & Co., dated February 21, 2023

Exhibit 1.1 Esperion Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 21, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to tim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Esperion Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

Amendment No. 2 to Security Agreement, by and among the Registrant, the purchasers party thereto, and Eiger III SA LLC, as the collateral agent and administrative agent, dated effective as of November 23, 2022

Exhibit 10.28 Execution Version WAIVER AND AMENDMENT NO. 3 TO REVENUE INTEREST PURCHASE AGREEMENT AND AMENDMENT NO. 2 TO SECURITY AGREEMENT This Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (this “Amendment”) is entered into by and among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), Eiger Partners II Fund, a sub-

ESPR / Esperion Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #1 Passive Investment

SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Esperion Therapeutics, Inc. (Tit

POWER OF ATTORNEY

EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Undersigned personally present.

ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to

ESPR / Esperion Therapeutics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 tm235037d9sc13ga.htm SC 13G/A CUSIP No: 29664W105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title

ESPR / Esperion Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Esperion Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 29664W105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f

ESPR / Esperion Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESPERION THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29664W105 (CUSIP Number) JANUARY 11, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results – Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H

Exhibit 99.1 Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results – Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals – – Fourth quarter 2022 U.S. net

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2023 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commis

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 23, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

Employment Agreement, dated November 16, 2022, by and between the Registrant and Benjamin Halladay (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on November 16, 2022)

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 16th day of November, 2022, by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and Benjamin Halladay (the ?Executive?). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2022 Esperion Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

Esperion Appoints Ben Halladay Chief Financial Officer

Exhibit 99.1 Esperion Appoints Ben Halladay Chief Financial Officer ANN ARBOR, Mich., November 16, 2022 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive managem

Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update – CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with

Exhibit 99.1 Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update – CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be Presented in March at the American College of Cardiology 72nd Annual Scientific Sessions – – U.S. Net Product

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2022 Esperion Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therape

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 20, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Com

Certificate of Validation relating to Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant dated May 26, 2022

Exhibit 3.1 CERTIFICATE OF VALIDATION OF CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ESPERION THERAPEUTICS, INC. Esperion Therapeutics, Inc., a Delaware corporation (the ?Corporation?), does hereby certify that: First: The defective corporate acts that are the subject of this Certificate of Validation are the amendment effected by, and the filing of, the Ce

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

ESPR / Esperion Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Esperion Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Val

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update – Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (

Exhibit 99.1 Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update ? Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 ? ? U.S. Net Product Revenue of NEXLETOL? (bempedoic acid) Tablets and NEXLIZET? (bempedoic acid and ezetimibe) Tablets grew 28% Y/Y to $13.6 Million in the Second Quarter 2022 ? ?

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

Employment Agreement, dated June 9, 2022, by and between the Registrant and Eric Warren (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on June 13, 2022)

Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and Eric J. Warren (the ?Executive?). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regar

Employment Agreement, dated June 9, 2022, by and between the Registrant and Sheldon Koenig (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on June 13, 2022)

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and Sheldon L. Koenig (the ?Executive?). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company re

Employment Agreement, dated June 9, 2022, by and between the Registrant and Benjamin Looker (incorporated by reference to Exhibit 10.4 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on June 13, 2022)

Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and Benjamin O. Looker (the ?Executive?). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company r

Employment Agreement, dated June 9, 2022, by and between the Registrant and JoAnne Foody (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K, File No. 001-35986, filed on June 13, 2022)

Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and JoAnne Foody (the ?Executive?). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regardi

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

Exhibit 99.1 Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion?s Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders. "On behalf of the

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

2022 Stock Option and Incentive Plan and forms of agreements thereunder (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-265247) filed on May 26, 2022)

Exhibit 99.1 ESPERION THERAPEUTICS, INC. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Esperion Therapeutics, Inc. (the ?Company?) a

As filed with the Securities and Exchange Commission on May 26, 2022

As filed with the Securities and Exchange Commission on May 26, 2022 Registration No.

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ESPERION THERAPEUTICS, INC. (Pursuant to Section 242 of the Delaware General Corporation Law) Esperion Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the ?DGCL?), does hereby certify as follows: A r

ESPR / Esperion Therapeutics Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

Esperion Reports First Quarter 2022 Financial Results and Provides Company Update – Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid a

Exhibit 99.1 Esperion Reports First Quarter 2022 Financial Results and Provides Company Update ? Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation? ? U.S. Net Product Revenue of NEXLETOL? (bempedoic acid) Tablets and NEXLIZET? (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022? ? Retail Prescription Equivalents Grew 56.7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutic

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors

Exhibit 99.1 Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern?s retirem

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 28, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commiss

Esperion Therapeutics, Inc. 3891 Ranchero Drive, Suite 150 Ann Arbor, MI 48108

CORRESP 1 filename1.htm Esperion Therapeutics, Inc. 3891 Ranchero Drive, Suite 150 Ann Arbor, MI 48108 April 22, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Esperion Therapeutics, Inc.: Registration Statement on Form S-3 filed April 15, 2022 (File No. 333-264303) Ladies and Gentlemen: Pur

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Esperion Therapeutics, Inc.

As filed with the Securities and Exchange Commission on April 15, 2022

S-3 1 tm2211216-1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 15, 2022 Registration No. 333-         UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ESPERION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or oth

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 tm229356d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, dated March 1, 2022, by and between Esperion Therapeutics, Inc. and Eric Warren.

EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 1st day of March, 2022, by and between Esperion Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Thera

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Comm

As filed with the Securities and Exchange Commission on February 22, 2022

S-8 1 esprs-8.htm S-8 As filed with the Securities and Exchange Commission on February 22, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ESPERION THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1870780 (State or Other Jurisdiction of Incorporat

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Esperion Therapeutics, Inc.

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update – Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets a

Exhibit 99.1 Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update ? Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 ? ? U.S. Net Product Revenue of NEXLETOL? (bempedoic acid) Tablets and NEXLIZET? (bempedoic acid and ezetimibe) Tablets Grew 12% Sequentially to $12.2 Million in the Fourth Quarter 2021 and Over 200% for t

ESPR / Esperion Therapeutics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 29664W105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29664W105 (CUSIP

ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment

United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi

ESPR / Esperion Therapeutics Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

ESPR / Esperion Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0839-esperiontherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Esperion Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 29664W105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update – Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Ac

Exhibit 99.1 Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update – Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million – – Company Reiterates F

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2022 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commis

, by and between Esperion Therapeutics, Inc. and

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and Benjamin O. Looker (the ?Executive?). 1.Start Date; Employment Term. The Company and the Executive desire to enter into an employment relationship, pursuant to this Agreement commencing as of January 4, 2022, unless another date i

Esperion Appoints Benjamin O. Looker as General Counsel – Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones –

Exhibit 99.1 Esperion Appoints Benjamin O. Looker as General Counsel ? Addition to management team brings experienced strategic legal counsel as Company nears pivotal milestones ? ANN ARBOR, Mich., January 4, 2022 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as a member of the Esper

ESPR / Esperion Therapeutics Inc / CVI Investments, Inc. - SCHEDULE 13G Passive Investment

CUSIP No: 29664W105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29664W105 (CUSIP N

ESPR / Esperion Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Entry into a Material Definitive Agreement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

ESPR / Esperion Therapeutics Inc / Flynn James E Passive Investment

SC 13G 1 e621139sc13g-esperion.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.) * Esperion Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29664

Underwriting Agreement, dated December 2, 2021, between Esperion Therapeutics, Inc. and H.C. Wainwright & Co., LLC

Exhibit 1.1 Esperion Therapeutics, Inc. 32,142,858 Shares of Common Stock (par value $0.001 per share) No Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 32,142,858 Shares of Common Stock Underwriting Agreement December 2, 2021 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule A hereto 430 Park Avenue, 3rd Floor New York, NY

Form of Warrant to Purchase Common Stock.

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ESPERION THERAPEUTICS, Inc. Warrant Shares: Issue Date: December 7, 2021 Initial Exercise Date: December 7, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Esperion Announces Proposed Public Offering

Exhibit 99.1 Esperion Announces Proposed Public Offering ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) (?Esperion? or the ?Company?), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in an underwritten public

Esperion Announces Pricing of $225 Million Public Offering

Exhibit 99.2 Esperion Announces Pricing of $225 Million Public Offering ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) (?Esperion? or the ?Company?), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Eac

CALCULATION OF REGISTRATION FEE

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5)? Registration No. 333-258397? CALCULATION OF REGISTRATION FEE ? ? Title of Each Class of Securities to be Registered ? ? ? Amount to be Registered ? ? ? Proposed Maximum OfferingPrice Per Security ? ? ? Proposed Maximum Aggregate Offering Price ? ? ? Amount of Registration Fee(1) ? Common Stock, par value $0.001 per share ? ? ? ? ? 36,964,286(2) ?

Subject to Completion Preliminary Prospectus Supplement dated December 2, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therape

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update – Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR

Exhibit 99.1 Contact: Ben Church [email protected] 734-864-6774 Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update ? Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth ? ? Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) A

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors

Exhibit 99.1 Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors ANN ARBOR, Mich., November 1, 2021 (GLOBE NEWSWIRE) - Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to welcome Seth to the

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock

EX-99.1 3 tm2130916d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock ANN ARBOR, Mich., October 25, 2021 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (th

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

Exchange Agreement, dated October 22, 2021, by and between Esperion Therapeutics, Inc. and the Holders

EX-10.1 2 tm2130916d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version Exchange Agreement October 22, 2021 Esperion Therapeutics, Inc. 4.00% Convertible Senior Subordinated Notes due 2025 Each undersigned investor (each, an “Exchanging Investor”), hereby agrees to exchange, with Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), certain 4.00% Convertible Senior Subordinated

ESPERION Announces Plan for Transformative Long-Term Growth –Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workfo

Exhibit 99.1 ESPERION Announces Plan for Transformative Long-Term Growth ?Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial? ?Reduces overall workforce by 40 percent and further shifts marketing strategy towards a greater proportion of digital and virtual outreach? ?Significant operat

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on August 3, 2021

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 3, 2021 Registration No.

Form of Senior Indenture between Registrant and one or more trustees to be named

EX-4.3 3 tm2123538d2ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 ESPERION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 3 Section 1.01 Definitions of Terms 3 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 6 Section 2.01 Designation and Terms of Securities 6 Section 2.02 F

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.3 ESPERION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 3 Section 1.01 Definitions of Terms 3 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 6 Section 2.01 Designation and Terms of Securities 6 Section 2.02 Form of Securities and Trustee’s Certificat

License and Collaboration Agreement, by and between the Registrant and Daiichi Sankyo Company, Limited dated April 26, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, File No. 001-35986, filed on August 3, 2021)

EX-10.1 2 ex101-licenseandcollaborat.htm EX-10.1 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED AGREEMENT by and between Daiichi Sankyo Company, Limited and ESPERION THE

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.4 ESPERION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Cert

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – – Growth

Exhibit 99.1 Contact: Kaitlyn Brosco ESPERION [email protected] ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update ? U.S. Net Product Revenue of NEXLETOL? (bempedoic acid) Tablets and NEXLIZET? (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million ? ? Growth Driven by Increase in Demand and Substantial Improvement in Net Price ? ?Pre

As filed with the Securities and Exchange Commission on August 3, 2021

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 3, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics

Sales Agreement, dated as of August 3, 2021, between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENT August 3, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.4 ESPERION THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Cert

ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108 (734) 887-3903

RW 1 tm2123538d3rw.htm RW ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108 (734) 887-3903 August 3, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: Esperion Therapeutics, Inc. – Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-258396 ) Ladies and Gentlemen: Pursua

Amended and Restated Employment Agreement by and between the Registrant and Sheldon Koenig dated May 14, 2021

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc.

Sales Agreement, dated as of August 3, 2021, between the Registrant and Jefferies LLC

EX-1.2 2 tm2123538d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENT August 3, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

Exhibit 99.1 ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer June 28, 2021 – Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline – ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) - ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, F

Employment Agreement by and between the Registrant and JoAnne Foody dated June 28, 2021

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made by and between Esperion Therapeutics, Inc., a Delaware corporation (the ?Company?), and JoAnne Foody (the ?Executive?). 1.Start Date; Employment Term. The Company and the Executive desire to enter into an employment relationship, pursuant to this Agreement commencing as of June 28, 2021, unless another date is agreed

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 27, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

ESPR / Esperion Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A 1 d174120dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* ESPERION THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29664W105 (CUSIP Number) May 19, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to design

ESPERION Appoints Sheldon Koenig as President and CEO -- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served

Exhibit 99.1 ESPERION Appoints Sheldon Koenig as President and CEO - Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO - - Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor ? ANN ARBOR, Mich., May 17, 2021 (GLOBE NEWSWIRE) -

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commissio

Agreement dated May 15, 2021 by and between Esperion Therapeutics, Inc. and Tim M. Mayleben.

Exhibit 10.1 May 15, 2021 Tim Mayleben Re: CEO Departure Agreement Dear Tim: This letter confirms that you will be leaving your role as President and Chief Executive Officer of Esperion Therapeutics, Inc. (the ?Company?), effective May 17, 2021 (the ?Date of Termination?). The Board of Directors of the Company (the ?Board?) appreciates your substantial contributions to the Company and would like t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2021 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35986 26-1870780 (State or other jurisdiction of incorporation) (Commission

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update – U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (be

Exhibit 99.1 Contact: Kaitlyn Brosco ESPERION [email protected] ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update ? U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price ? ? Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL? (bempedoic acid) Tablets and NEXLIZET? (bempedoic acid and ezetimibe) Tablets ?

Second Amended and Restated Bylaws of the Registrant dated April 29, 2021

Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF ESPERION THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date an

2nd Amendment to the License and Collaboration Agreement by and between the Registrant and Daiichi Sankyo Europe GMBH dated March 19, 2021

EX-10.1 3 ex1012ndamendmentdseagreem.htm EX-10.1 Exhibit 10.1 2ND AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT by and between DAIICHI SANKYO EUROPE GMBH and ESPERION THERAPEUTICS, INC. March 19th, 2021 This 2nd AMENDMENT to the LICENSE AND COLLABORATION AGREEMENT (this “2nd Amendment”), entered into as of March 19th, 2021 (“2nd Amendment Effective Date”), is by and between Daiichi Sankyo E